Literature DB >> 14676816

Integrin-linked kinase (ILK) expression in human colon cancer.

V Bravou, G Klironomos, E Papadaki, D Stefanou, J Varakis.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14676816      PMCID: PMC2395290          DOI: 10.1038/sj.bjc.6601482

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


× No keyword cloud information.
Sir, In a recent study, Marotta reported integrin-linked kinase (ILK) overexpression and dysregulation of ILK signalling in sporadic human colon cancer. It was concluded that the dysregulation of ILK signalling is an important early event in the development of the disease. We studied ILK expression in 84 human colorectal tumours (four adenomas and 80 carcinomas) by immunohistochemistry in order to assess whether ILK is involved in the development and progression of human colorectal carcinoma. Paraffin-embedded tissue samples were retrieved from the files of the Departments of Pathology, ‘Agios Andreas’ General Hospital, Patras, Greece and University Hospital of Ioannina, Ioannina, Greece. Clinicopathologic parameters were obtained from the pathology reports. Carcinomas were graded as: well, moderately and poorly differentiated on the basis of the degree of gland formation and staged according to the Astler Coller staging system. Immunohistochemical analysis was carried out using a standard streptavidin–biotin–peroxidase technique. Primary polyclonal anti-ILK antibody was obtained from Upstate Biotechnology (dilution 1 : 500), and immunodetection was performed with StrAvigen Multilink Immunodetection system B-SA (Biogenex) using DAB as the chromogen. Negative and positive controls were used in the study. The immunostaining intensity was evaluated by light microscopy and scored as negative (−), weak (+), moderate (++) and strong (+++). Statistical analysis was performed with SPSS 10 for Windows. Relationships between ILK expression and clinicopathologic parameters were evaluated by one-way ANOVA and Tukey test post-hoc analysis. P-values<0.05 were considered to be significant. There was no ILK immunoreactivity in the normal colonic epithelium (Figure 1A, B), while the majority of adenomas (75%) and in situ carcinomas (83.3%) were ILK positive (Figure 1C, D). All invasive carcinomas were positive (Figure 1E, F). The levels of expression were significantly higher in invasive compared with noninvasive lesions (P<0.001). The intensity of ILK expression was also correlated with the depth of invasion (P<0.001), presence of lymph node metastasis (P<0.01), tumour grade (P<0.001) (Figure 2) and overall staging (P<0.001) (Table 1 ). In all positive lesions, >90% of tumour cells were stained (diffuse pattern) and ILK immunostaining was confined to the cytoplasm.
Figure 1

Integrin-linked kinase expression in human colorectal tumours. (A) Normal colonic epithelium with no ILK immunoreactivity (× 200). (B) Integrin-linked kinase-positive cancerous crypts compared with ILK-negative normal crypts (× 200). (C, D) Weak (+) immunostaining in an adenoma and an in situ carcinoma, respectively (× 200). (E, F) Invasive carcinomas demonstrating strong (+++) immunostaining (× 200).

Figure 2

Integrin-linked kinase expression increases with tumour grade. (A) A well-differentiated colorectal carcinoma demonstrating weak (+) ILK expression (× 200). (B) Moderate levels of expression (++) in a moderately differentiated tumour (× 200). (C) High levels of expression (+++) in a poorly differentiated neoplasm (× 200).

Table 1

Integrin-linked kinase expression in human colorectal tumours. Correlation with clinicopathologic parameters

  ILK expression
 
  
+
++
+++
 
 Nn%n%n%n%P-valuea
Adenomas total41(25)3(75)0(0)0(0) 
Carcinomas total802(2.5)23(28.7)40(50)15(18.8) 
Invasive680(0)18(26.5)35(51.5)15(22)<0.001
In situ122(16.6)5(41.7)5(41.7)0(0) 
Depth of invasion<0.001
 Tis122(16.6)5(41.7)5(41.7)0(0) 
 T1+T280(0)5(62.5)3(37.5)0(0) 
 T3+T4600(0)13(21.7)32(53.3)15(25) 
Lymph node metastasis350(0)7(20)16(45.7)12(34.3)<0.01
           
Grade<0.001
 Well differentiated162(12.5)8(50)6(37.5)0(0) 
 Moderately differentiated370(0)10(27)21(56.8)6(10.2) 
 Poorly differentiated270(0)5(18.5)13(48.2)9(33.3) 
           
Astler Coller stage<0.001
 A122(16.6)5(41.7)5(41.7)0(0) 
 B180(0)5(62.5)3(37.5)0(0) 
 B2250(0)6(24)16(64)3(12) 
 C100(0)0(0)0(0)0(0) 
 C2350(0)7(20)16(45.7)12(34.3) 

One-way ANOVA. P-value<0.05 statistically significant.

Integrin-linked kinase expression in human colorectal tumours. (A) Normal colonic epithelium with no ILK immunoreactivity (× 200). (B) Integrin-linked kinase-positive cancerous crypts compared with ILK-negative normal crypts (× 200). (C, D) Weak (+) immunostaining in an adenoma and an in situ carcinoma, respectively (× 200). (E, F) Invasive carcinomas demonstrating strong (+++) immunostaining (× 200). Integrin-linked kinase expression increases with tumour grade. (A) A well-differentiated colorectal carcinoma demonstrating weak (+) ILK expression (× 200). (B) Moderate levels of expression (++) in a moderately differentiated tumour (× 200). (C) High levels of expression (+++) in a poorly differentiated neoplasm (× 200). One-way ANOVA. P-value<0.05 statistically significant. Our results seem to indicate that, in addition to being involved in the initiation of colon carcinogenesis, as suggested by Marotta , ILK may also be implicated in the progression, invasiveness and metastatic potential of colorectal cancer. Thus, ILK may prove to be a useful prognostic marker for these tumours.
  1 in total

1.  Characterisation of integrin-linked kinase signalling in sporadic human colon cancer.

Authors:  A Marotta; K Parhar; D Owen; S Dedhar; B Salh
Journal:  Br J Cancer       Date:  2003-06-02       Impact factor: 7.640

  1 in total
  14 in total

1.  Genome-wide methylation profiling and the PI3K-AKT pathway analysis associated with smoking in urothelial cell carcinoma.

Authors:  Mariana Brait; Enrico Munari; Cynthia LeBron; Maartje G Noordhuis; Shahnaz Begum; Christina Michailidi; Nilda Gonzalez-Roibon; Leonel Maldonado; Tanusree Sen; Rafael Guerrero-Preston; Leslie Cope; Paola Parrella; Vito Michele Fazio; Patrick K Ha; George J Netto; David Sidransky; Mohammad O Hoque
Journal:  Cell Cycle       Date:  2013-02-22       Impact factor: 4.534

2.  Integrin-Linked-Kinase Overexpression Is Implicated in Mechanisms of Genomic Instability in Human Colorectal Cancer.

Authors:  Panagiota Chadla; Marina Arbi; Sofia Nikou; Theodoros Kalliakoudas; Helen Papadaki; Stavros Taraviras; Zoi Lygerou; Vasiliki Bravou
Journal:  Dig Dis Sci       Date:  2020-06-03       Impact factor: 3.199

3.  ILK Expression in Colorectal Cancer Is Associated with EMT, Cancer Stem Cell Markers and Chemoresistance.

Authors:  Dimitrios Tsoumas; Sofia Nikou; Efstathia Giannopoulou; Spyridon Champeris Tsaniras; Chaido Sirinian; Ioannis Maroulis; Stavros Taraviras; Vassiliki Zolota; Haralabos P Kalofonos; Vasiliki Bravou
Journal:  Cancer Genomics Proteomics       Date:  2018 Mar-Apr       Impact factor: 4.069

4.  Expression of integrin-linked kinase in lung squamous cell carcinoma and adenocarcinoma: correlation with E-cadherin expression, tumor microvessel density and clinical outcome.

Authors:  Juanhan Yu; Rui Shi; Daorong Zhang; Enhua Wang; Xueshan Qiu
Journal:  Virchows Arch       Date:  2010-12-07       Impact factor: 4.064

5.  Cooperative signaling between Wnt1 and integrin-linked kinase induces accelerated breast tumor development.

Authors:  Arusha Oloumi; Mykola Maidan; Frances E Lock; Howard Tearle; Steven McKinney; William J Muller; Samuel A J R Aparicio; Shoukat Dedhar
Journal:  Breast Cancer Res       Date:  2010-06-21       Impact factor: 6.466

6.  Overexpression of integrin-linked kinase promotes lung cancer cell migration and invasion via NF-κB-mediated upregulation of matrix metalloproteinase-9.

Authors:  Mingjing Zhao; Ying Gao; Lingling Wang; Shuo Liu; Bing Han; Lie Ma; Yuan Ling; Shitao Mao; Xiaoge Wang
Journal:  Int J Med Sci       Date:  2013-06-14       Impact factor: 3.738

7.  Suppression of Her2/neu expression through ILK inhibition is regulated by a pathway involving TWIST and YB-1.

Authors:  J Kalra; B W Sutherland; A L Stratford; W Dragowska; K A Gelmon; S Dedhar; S E Dunn; M B Bally
Journal:  Oncogene       Date:  2010-09-13       Impact factor: 9.867

8.  The small molecule inhibitor QLT0267 Radiosensitizes squamous cell carcinoma cells of the head and neck.

Authors:  Iris Eke; Franziska Leonhardt; Katja Storch; Stephanie Hehlgans; Nils Cordes
Journal:  PLoS One       Date:  2009-07-30       Impact factor: 3.240

9.  Inhibitory Effects of PEI-RGD/125I-(αv) ASODN on Growth and Invasion of HepG2 Cells.

Authors:  Haidong Cai; Yu Qiao; Ming Sun; Xueyu Yuan; Qiong Luo; Yuehua Yang; Shidong Yuan; Zhongwei Lv
Journal:  Med Sci Monit       Date:  2015-08-10

Review 10.  Contributions of integrin-linked kinase to breast cancer metastasis and tumourigenesis.

Authors:  Cimona V Hinton; Shalom Avraham; Hava Karsenty Avraham
Journal:  J Cell Mol Med       Date:  2008-03-19       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.